Cantor Fitzgerald Comments on MiMedx Group FY2026 Earnings

MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for MiMedx Group in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of $0.40 for the year. Cantor Fitzgerald has a "Overweight" rating and a $13.00 price objective on the stock. The consensus estimate for MiMedx Group's current full-year earnings is $0.30 per share.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. The business had revenue of $88.21 million during the quarter, compared to the consensus estimate of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%.

Separately, Wall Street Zen raised shares of MiMedx Group from a "hold" rating to a "buy" rating in a report on Friday.

MiMedx Group Stock Up 1.2%

MDXG traded up $0.08 during midday trading on Tuesday, reaching $6.53. 340,554 shares of the company were exchanged, compared to its average volume of 686,371. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The company's fifty day moving average price is $6.80 and its 200 day moving average price is $8.01. MiMedx Group has a one year low of $5.47 and a one year high of $10.14. The company has a market cap of $964.49 million, a price-to-earnings ratio of 11.87 and a beta of 1.82.

Insider Activity

In related news, CAO William Frank Iv Hulse sold 54,596 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the sale, the chief accounting officer now owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. This represents a 11.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Joseph H. Capper purchased 200,000 shares of the firm's stock in a transaction dated Friday, May 2nd. The stock was purchased at an average cost of $6.34 per share, for a total transaction of $1,268,000.00. Following the acquisition, the chief executive officer now owns 529,530 shares of the company's stock, valued at approximately $3,357,220.20. This trade represents a 60.69% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 60,461 shares of company stock valued at $477,301 over the last quarter. Company insiders own 1.70% of the company's stock.

Institutional Trading of MiMedx Group

A number of hedge funds have recently made changes to their positions in the stock. Paradigm Capital Management Inc. NY lifted its holdings in shares of MiMedx Group by 0.5% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock worth $45,082,000 after acquiring an additional 22,131 shares during the last quarter. Cannell Capital LLC lifted its stake in MiMedx Group by 1.1% in the fourth quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock worth $35,012,000 after purchasing an additional 40,235 shares during the last quarter. First Light Asset Management LLC boosted its position in MiMedx Group by 3.3% during the first quarter. First Light Asset Management LLC now owns 3,453,074 shares of the company's stock valued at $26,243,000 after buying an additional 109,213 shares during the period. Renaissance Technologies LLC boosted its position in MiMedx Group by 18.4% during the fourth quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock valued at $17,360,000 after buying an additional 280,327 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of MiMedx Group by 15.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock valued at $17,338,000 after buying an additional 238,075 shares during the last quarter. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.